Professor Raj Narayan, Chairman of the Department of Neurosurgery at Northwell, a co-author of the study, and a member of the Helius Scientific Advisory Board, stated, "Our independent work with trigeminal nerve stimulation in an experimental laboratory model has demonstrated very encouraging results with neuromodulation as a potential therapy for TBI. Should these benefits be realized in people who have suffered a TBI, it would be a significant step forward in developing a novel therapeutic approach to a disease in which pharmacological treatments have so far failed to show a significant benefit."
About PoNS™ Investigational Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated by Helius in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate TBI.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. Helius intends to seek FDA clearance for commercial distribution for the PoNS™ device for the treatment of balance disorder due to mild to moderate TBI. For more information, please visit www.heliusmedical.com.
The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forwardlooking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws ("forward-looking statements").
All statements other than statements of historical fact included in this news release are forwardlooking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory submissions and approvals or other business initiatives and objectives.
Forward-looking statements are often identified by terms such as "estimate" "intend" and similar expressions.
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